Clinical Trials
38 trialsEndoBARR
Medical College of Wisconsin
Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
University of Colorado, Denver
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
Grupo Español de Investigación en Cáncer de Ovario
CheckMate 9KD
Bristol-Myers Squibb
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
Memorial Sloan Kettering Cancer Center
TRITON3
pharmaand GmbH
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
University of Michigan Rogel Cancer Center
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
National Institutes of Health Clinical Center (CC)
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
MAMOC
North Eastern German Society of Gynaecological Oncology
Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
University of Kentucky
TRIUMPH
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors
University of Arizona
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Hoosier Cancer Research Network
CATCH-R
pharmaand GmbH
Clovis-001
University of Oklahoma
A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Hoffmann-La Roche
RAMP
pharmaand GmbH
A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
pharmaand GmbH
ARIEL2
pharmaand GmbH
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
pharmaand GmbH
ARIEL3
pharmaand GmbH
DDI
pharmaand GmbH
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
FRACTION-GC
Bristol-Myers Squibb
TRITON2
pharmaand GmbH
AME
pharmaand GmbH
A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
pharmaand GmbH
Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor
pharmaand GmbH
A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens
pharmaand GmbH
Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives
pharmaand GmbH
Arterial Hypertension Related to PARP Inhibitors (ArteRIB)
University Hospital, Caen
Pancytopenia Related to PARP Inhibitors (PancytoRIB)
University Hospital, Caen
RUBY
UNICANCER
Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair
University of California, San Francisco
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
Hoffmann-La Roche
Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
Cancer Research UK